AGLE - Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
- Aeglea BioTherapeutics ( NASDAQ: AGLE ) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency.
- Shares of the micro-cap clinical-stage biotech soared 57.5% to $0.80 in postmarket trading.
- The application was submitted by AGLE's commercialization partner in Europe and Middle East, Immedica Pharma, AGLE said in a statement .
- Arginase 1 deficiency is a rare, inherited disorder in which there is complete or partial lack of the enzyme arginase in the liver and red blood cells.
- Aeglea ( AGLE ) earlier in Aug. reported a mixed set of Q2 results .
For further details see:
Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase